Pi­ra­mal Phar­ma So­lu­tions picks up In­di­an pep­tide API mak­er in push in­to on­col­o­gy, meta­bol­ic con­tract work

Pep­tide ther­a­peu­tics have been a hot area for in­vest­ment in re­cent years, and con­tract man­u­fac­tur­ing play­ers are ramp­ing up ca­pac­i­ty to meet grow­ing de­mand. In­dia’s Pi­ra­mal Phar­ma So­lu­tions, fresh off a ma­jor cash in­fu­sion last sum­mer, is now ab­sorb­ing a spe­cial­ized API play­er to help ex­pand its of­fer­ings there.

In­dia’s Pi­ra­mal will dole out $106 mil­lion plus fu­ture mile­stones for Hem­mo Phar­ma­ceu­ti­cals, which the CD­MO called “one of the few pure-play syn­thet­ic pep­tide API man­u­fac­tur­ers in the glob­al mar­ket­place,” as part of a big­ger push in­to con­tract work in on­col­o­gy and meta­bol­ic ther­a­pies, the com­pa­nies said Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER